[1]赵忆,邢磊,邢文文.康艾注射液联合SOX化疗方案治疗晚期胃癌的临床研究[J].西部中医药,2024,37(02):153-156.[doi:10.12174/j.issn.2096-9600.2024.02.30]
　ZHAO Yi,XING Lei,XING Wenwen.Clinical Study of Kang′ai Injection Combined with SOX Chemotherapy in the Treatment of Advanced Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2024,37(02):153-156.[doi:10.12174/j.issn.2096-9600.2024.02.30]
点击复制

康艾注射液联合SOX化疗方案治疗晚期胃癌的临床研究
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年02期
页码:
153-156
栏目:
衷中参西
出版日期:
2024-02-15

文章信息/Info

Title:
Clinical Study of Kang′ai Injection Combined with SOX Chemotherapy in the Treatment of Advanced Gastric Cancer
作者:
赵忆1, 邢磊2, 邢文文2
1.淮安市第二人民医院，江苏 淮安 223000
2.南京市高淳中医院，江苏 南京 211300
Author(s):
ZHAO Yi1, XING Lei2, XING Wenwen2
1.Huai'an Second People's Hospital, Huai'an 223000, China
2.Gaochun Hospital of Traditional Chinese Medicine, Nanjing 211300, China
关键词:
胃癌; 晚期; 康艾注射液; 替吉奥; 奥沙利铂; 化疗方案; 临床研究
Keywords:
gastric cancer;  advanced; injection; Tegafur;  gimeracil and oteracil potassium capsules; oxaliplatin; chemotherapy; clinical study
分类号:
R735
DOI:
10.12174/j.issn.2096-9600.2024.02.30
文献标志码:
B
摘要:
目的观察康艾注射液联合SOX（替吉奥和奥沙利铂）化疗方案治疗晚期胃癌的临床疗效。 方法选择100例同意化疗的晚期胃癌患者，通过随机数字表法分为对照组和观察组，每组50例。对照组使用SOX治疗方案，静注奥沙利铂注射液，同时口服替吉奥胶囊。观察组在对照组基础上联合静脉注射康艾注射液，两组均连续治疗14天，停药7天，以21天为1个治疗周期，连续治疗3个周期。观察两组临床总有效率、疾病控制率、血清肿瘤标记物水平、卡式（Karnofsky，KPS）评分及不良反应发生率。 结果治疗3个周期后，观察组总有效率［64.0%（32/50）］优于对照组［48.0%（24/50）］（P＜0.05）；观察组疾病控制率［84.0%（42/50）］优于对照组［70.0%（35/50）］（P＜0.05）。治疗后，观察组血清肿瘤标志物癌胚抗原（carcinoembryonic antigen，CEA）、糖类抗原199（carbohydrate antigen199，CA199）、糖类抗原724（carbohydrate antigen724，CA724）水平低于对照组，KPS评分高于对照组（P＜0.05）；观察组不良反应发生率［28.0%（14/50）］低于对照组［42.0%（21/50）］（P＜0.05）。 结论康艾注射液联合SOX化疗方案治疗晚期胃癌可降低患者肿瘤标志物水平，提高其生活质量，减少不良反应发生率。
Abstract:
ObjectiveTo observe clinical effects of Kang'ai injection joined with SOX (Tegafur, gimeracil and oteracil potassium capsules and oxaliplatin) chemotherapy in the treatment of advanced gastric cancer. MethodsOne hundred patients with advanced gastric cancer who agreed to chemotherapy were selected, and allocated to the control group and the observation group according to random number table method, with 50 cases in each group. The control group used SOX therapeutic regimen, intravenous injection of oxaliplatin for injection, meanwhile oral administration of Tegafur, gimeracil and oteracil potassium capsules. The observation group accepted intravenous injection of Kang'ai injection, both groups were treated for 14 days consecutively, seven days' break, 21 days were one course of the treatment, for three therapeutic cycles continuously. To observe clinical total effective rate, disease control rate, the levels of serum tumor markers, KPS scores and the incidence of adverse reaction of the two groups. ResultsAfter three therapeutic cycles, total effective rate of the observation group was [64.0%(32/50)], better than [48.0%(24/50)] of the control group (P<0.05); disease control rate of the observation group was [84.0%(42/50)], higher than [70.0%(35/50)] of the control group (P<0.05). After the treatment, the levels of CEA, CA199 and CA724 of the observation group were lower than these of the control group, KPS scores higher than these of the control group (P<0.05); the incidence of adverse reaction of the observation group was [28.0%(14/50)], lower than [42.0%(21/50)] of the control group (P<0.05). ConclusionKang'ai injection combined with SOX chemotherapy could lower the levels of tumor markers, raise the patients' quality of life and reduce the incidence of adverse reaction in the treatment of advanced gastric cancer.

相似文献/References:

[1]熊墨年,唐晓玲,余炅,等.益气清毒法联合化疗治疗中晚期胃癌的临床观察[J].西部中医药,2011,24(11):35.
[2]李晶,刘小军,赵达△.康莱特软胶囊联合化疗治疗晚期卵巢癌的临床研究[J].西部中医药,2013,26(01):1.
　LI Jing,LIU Xiaojun,ZHAO Da.Clinical Study on KangLaiTe Soft Capsule and Chemotherapy in Treating Ovarian Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(02):1.
[3]张小仙,倪角角,陈辉.舒适护理在晚期胃癌患者中的应用[J].西部中医药,2012,25(12):105.
　ZHANG Xiao-xian,NI Jiao-jiao,CHEN Hui.Application of Comfort Care to the Patients with Gastric Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2012,25(02):105.
[4]王宏伟,程小丽,许雅清,等.苦马豆素对胃癌细胞中pten和survivin mRNA表达的影响[J].西部中医药,2015,28(12):25.
[5]胡玥,刘沈林.刘沈林教授“胃肾同治”理论探讨及其在胃癌中的应用[J].西部中医药,2015,28(10):72.
[6]朱剑梅,李世军.莲芪胶囊配合化疗治疗胃癌的临床研究[J].西部中医药,2015,28(12):91.
[7]贡惠娟,赵玉娥,严春亚,等.循证护理对中晚期肺癌患者睡眠质量和自我护理能力的影响[J].西部中医药,2015,28(12):121.
[8]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(02):1.
[9]赵航,戴玮,张华军.顾护胃气法改善晚期恶性肿瘤患者生活质量观察[J].西部中医药,2014,27(05):83.
　ZHAO Hang,DAI Wei,ZHANG Huajun.Observation on Improving Life Quality of the Patients with Advanced Malignant Tumors by Protecting Stomach-Qi Method[J].Western Journal of Traditional Chinese Medicine,2014,27(02):83.
[10]李雅娟.围手术期护理对胃癌根除术患者护理质量的影响[J].西部中医药,2012,25(12):113.
　LI Ya-juan.Influence of Perioperative Care on Nursing Quality of Patients Undergoing Radical Resection of Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2012,25(02):113.
[11]冯天明,王尔全,吴大平.血 汤加减联合西药对晚期胃癌患者血清CEA、CA199的影响[J].西部中医药,2021,34(08):126.[doi:10.12174/j.issn.2096-9600.2021.08.29]
　FENG Tianming,WANG Erquan,WU Daping.Effects of Modified Xuezhen Decoction Combined with Western Medicine on Serum CEA and CA199 in Patients with Advanced Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(02):126.[doi:10.12174/j.issn.2096-9600.2021.08.29]

备注/Memo

备注/Memo:
赵忆（1987—），男，医师。研究方向：肿瘤疾病的中医药防治。南京市中医药青年人才培养计划项目（ZYQ20065）。
更新日期/Last Update: 2024-02-15